What's Happening?
MyOme has introduced the Prostate Cancer Integrated Polygenic Risk Score (iPRS) test, aimed at identifying men at elevated genetic risk for prostate cancer. This innovative test combines data from millions of genetic markers with clinical risk factors
to provide personalized risk assessments. The iPRS test is designed for men aged 30 to 75 who have no personal history of prostate cancer and no pathogenic variants in known prostate cancer-associated genes. The test offers a more precise understanding of prostate cancer risk, enabling earlier detection and personalized prevention strategies. MyOme's internal validation showed that 8.6% of men with no family history were identified as high risk, with a threefold higher incidence of prostate cancer compared to the non-risk group.
Why It's Important?
The launch of the iPRS test represents a significant advancement in prostate cancer detection and prevention. By providing a more accurate risk assessment, the test can help reduce unnecessary procedures and anxiety associated with traditional screening methods like PSA tests. This development is crucial for improving men's health outcomes, as prostate cancer is a major health concern with a significant genetic component. The test's ability to identify high-risk individuals who may not have known genetic variants offers a new avenue for proactive healthcare, potentially reducing the disease burden through early intervention.
